FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119422037> ?p ?o ?g. }

• W3119422037 endingPage "3459" @default.
• W3119422037 startingPage "3439" @default.
• W3119422037 abstract "The aim of this study is to rigorously review the efficacy and safety of olanzapine in defined hematology oncology settings including (1) the setting of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) settings (2) at 5 mg and 10 mg doses, and (3) for response rates for use in the acute, delayed, and overall settings post-MEC and HEC.Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched through April 23, 2020. The primary efficacy endpoints were the rate of complete response, in the acute (0-24 h post-chemotherapy), delayed (24-120 h post-chemotherapy), and overall (0-120 h post-chemotherapy) phases. The secondary efficacy endpoints were the rates of no nausea and no emesis, for each phase. Safety endpoints were the rate of no serious adverse events (i.e., no grade 3 or 4 toxicities), as assessed by Common Terminology Criteria for Adverse Events (CTCAE) criteria. The Mantel-Haenszel, random-effects analysis model was used to compute risk ratios and accompanying 95% confidence intervals for each endpoint. For endpoints that statistically favored one arm, absolute risk differences were computed to assess whether there is a 10% or greater difference, used as the threshold for clinical significance by MASCC/ESMO. Fragility indices were also calculated for each statistically significant endpoint, to quantitatively assess the robustness of the summary estimate. A cumulative meta-analysis was conducted for each efficacy meta-analysis with more than 5 studies, also using the Mantel-Haenszel random-effects analysis model.Three studies reported on olanzapine for the rescue of breakthrough chemotherapy-induced nausea and vomiting (CINV); 22 studies reported on olanzapine in the prophylactic setting. For studies reporting on HEC patients, olanzapine-containing regimens were statistically and clinically superior in seven of nine efficacy endpoints in the prophylaxis setting. When olanzapine is administered at a 10-mg dose, it is statistically and clinically superior to control patients in eight of nine endpoints among adults. Olanzapine may be effective in the MEC setting and when administered at 5-mg doses, but the paucity of data leads to notable uncertainty.Further RCTs are needed in the setting of MEC patients and administration of olanzapine at a lower 5-mg dose, which may be given to reduce the sedative effect of olanzapine at 10 mg." @default.
• W3119422037 created "2021-01-18" @default.
• W3119422037 creator A5001664608 @default.
• W3119422037 creator A5001776366 @default.
• W3119422037 creator A5005046506 @default.
• W3119422037 creator A5023362317 @default.
• W3119422037 creator A5033285318 @default.
• W3119422037 creator A5034842369 @default.
• W3119422037 creator A5035759347 @default.
• W3119422037 creator A5055466353 @default.
• W3119422037 creator A5076594436 @default.
• W3119422037 date "2021-01-13" @default.
• W3119422037 modified "2023-10-04" @default.
• W3119422037 title "Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature" @default.
• W3119422037 cites W1817463461 @default.
• W3119422037 cites W1930541576 @default.
• W3119422037 cites W1970880506 @default.
• W3119422037 cites W1985517071 @default.
• W3119422037 cites W1989801697 @default.
• W3119422037 cites W2004708268 @default.
• W3119422037 cites W2027393266 @default.
• W3119422037 cites W2028568939 @default.
• W3119422037 cites W2029309368 @default.
• W3119422037 cites W2030136010 @default.
• W3119422037 cites W2043380382 @default.
• W3119422037 cites W2045951807 @default.
• W3119422037 cites W2055125378 @default.
• W3119422037 cites W2060060301 @default.
• W3119422037 cites W2066209834 @default.
• W3119422037 cites W2074318951 @default.
• W3119422037 cites W2074600725 @default.
• W3119422037 cites W2080945325 @default.
• W3119422037 cites W2085539270 @default.
• W3119422037 cites W2116571828 @default.
• W3119422037 cites W2123267000 @default.
• W3119422037 cites W2134833483 @default.
• W3119422037 cites W2164832682 @default.
• W3119422037 cites W2164957370 @default.
• W3119422037 cites W2236401105 @default.
• W3119422037 cites W2269947642 @default.
• W3119422037 cites W2298619857 @default.
• W3119422037 cites W2345941356 @default.
• W3119422037 cites W2460792208 @default.
• W3119422037 cites W2507159129 @default.
• W3119422037 cites W2515000470 @default.
• W3119422037 cites W2527377692 @default.
• W3119422037 cites W2531089889 @default.
• W3119422037 cites W2587650025 @default.
• W3119422037 cites W2590295578 @default.
• W3119422037 cites W2591070772 @default.
• W3119422037 cites W2598945222 @default.
• W3119422037 cites W2726372533 @default.
• W3119422037 cites W2753167281 @default.
• W3119422037 cites W2753313580 @default.
• W3119422037 cites W2756578555 @default.
• W3119422037 cites W2788267648 @default.
• W3119422037 cites W2796322204 @default.
• W3119422037 cites W2800120257 @default.
• W3119422037 cites W2801626232 @default.
• W3119422037 cites W2804452466 @default.
• W3119422037 cites W2806372931 @default.
• W3119422037 cites W2890276558 @default.
• W3119422037 cites W2927120620 @default.
• W3119422037 cites W2942182297 @default.
• W3119422037 cites W2951408448 @default.
• W3119422037 cites W2971534105 @default.
• W3119422037 cites W2972411648 @default.
• W3119422037 cites W2977641350 @default.
• W3119422037 cites W2989713843 @default.
• W3119422037 cites W2996099006 @default.
• W3119422037 cites W2999377731 @default.
• W3119422037 cites W3000674753 @default.
• W3119422037 cites W3007545839 @default.
• W3119422037 cites W3010082243 @default.
• W3119422037 cites W3021250419 @default.
• W3119422037 cites W4243894673 @default.
• W3119422037 doi "https://doi.org/10.1007/s00520-020-05935-7" @default.
• W3119422037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7805431" @default.
• W3119422037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33442782" @default.
• W3119422037 hasPublicationYear "2021" @default.
• W3119422037 type Work @default.
• W3119422037 sameAs 3119422037 @default.
• W3119422037 citedByCount "15" @default.
• W3119422037 countsByYear W31194220372021 @default.
• W3119422037 countsByYear W31194220372022 @default.
• W3119422037 countsByYear W31194220372023 @default.
• W3119422037 crossrefType "journal-article" @default.
• W3119422037 hasAuthorship W3119422037A5001664608 @default.
• W3119422037 hasAuthorship W3119422037A5001776366 @default.
• W3119422037 hasAuthorship W3119422037A5005046506 @default.
• W3119422037 hasAuthorship W3119422037A5023362317 @default.
• W3119422037 hasAuthorship W3119422037A5033285318 @default.
• W3119422037 hasAuthorship W3119422037A5034842369 @default.
• W3119422037 hasAuthorship W3119422037A5035759347 @default.
• W3119422037 hasAuthorship W3119422037A5055466353 @default.
• W3119422037 hasAuthorship W3119422037A5076594436 @default.
• W3119422037 hasBestOaLocation W31194220371 @default.
• W3119422037 hasConcept C118552586 @default.

• next